Toward the end of each year, I make stem cell & regenerative medicine predictions for the coming year. It’s a fun tradition here on The Niche that goes way back. The stem cell field has changed dramatically as reflected in each year’s predictions. Here’s a list of past predictions with my grades of how they …
2023 stem cell & regenerative medicine predictions Read More »
It’s that time of year again when I grade my previous year’s predictions for the stem cell & regenerative medicine space. Overall, I did better than a typical year. I give the 2022 predictions an A- overall. This exercise can be kind of fun but also humbling. For example, I tend to be too optimistic …
Grading my 2022 regenerative medicine predictions Read More »
Viacord is one of the most well known firms in the for-profit cord blood banking industry. Today’s post is a review of the firm. I see concrete reasons for concern. What is Viacord? | Dubious autism claims | Viacord cost | Overall Review | References What is Viacord? As a cord blood banking firm, Viacord freezes …
Review of cord banker Viacord: dubious autism claims & other concerns Read More »
In today’s post I review the cord blood firm Cryo Cell International and discuss specific concerns I have about it. A major issue is their plan to open a clinic selling unproven cord cell infusions to kids. I believe this is risky both for the firm and more importantly for the children. What is Cryo …
Cryo Cell reviews: dubious cord cell clinic plans, risks, other issues Read More »
The last few years in the stem cell and regenerative medicine arena have been complicated in many ways. Variables like surging stem cell clinics and COVID have made predictions harder. Even so, trying to make predictions is useful and it’s fun to go over past year’s predictions. You can see my scorecard on my 2021 …
16 predictions for stem cells & regenerative medicine in 2022 Read More »
A quick review of the publicly-traded stem cell stocks I’ve been following in 2021 finds mostly discouraging news, but a few firms relatively outperformed the other publically-traded biotechs. One had some great news today. In this post, I’m doing a brief overview of how things went this year in the regenerative medicine space. I’m going …
2021 scorecard for stem cell stocks: REGN, VCEL, CCEL, LCTX did best Read More »
The other day I gave a talk in part about stem cell hype and mentioned as an example how the idea of already doing stem cell therapy for autism seems so misguided to me now. On the whole, in my view there are major downsides and risks for autistic kids whose parents are already having …
Fact-checking stem cell therapy for autism: still a risky idea Read More »
The journal Stem Cells Translational Medicine has a long track record of publishing great work. I also have a lot of respect for the editors there and I’ve published there myself. But a few recent events have sparked concerns including over possible undisclosed conflicts of interest in some papers there about cord blood for autism. …
Cord conflicts at the journal Stem Cells Translational Medicine Read More »
When my wife and I were expecting our first daughter way back in the nineties, we received a paper pamphlet about cord blood banking. Back then, I was a graduate student at UC San Diego School of Medicine working toward my Ph.D. in Molecular Pathology and my wife was in medical school at the time …
Fact-checking, pros and cons of cord blood banking Read More »